Breast cancer epidemiology and sociodemographic differences in BRICS-plus countries from 1990 to 2019: An age period cohort analysis.
APC
BRICS-plus
Breast cancer
DALYs
Mortality
Risk factors
Journal
SSM - population health
ISSN: 2352-8273
Titre abrégé: SSM Popul Health
Pays: England
ID NLM: 101678841
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
08
04
2023
revised:
18
04
2023
accepted:
29
04
2023
medline:
22
5
2023
pubmed:
22
5
2023
entrez:
22
5
2023
Statut:
epublish
Résumé
Breast cancer (BC) is a major health concern in the BRICS-plus, a group of developing nations consisting of Brazil, Russia, India, China, South Africa, and 30 other Asian countries, with nearly half of the world's population. This study aims to identify potential risk factors contributing to the burden of BC by assessing its epidemiological and socio-demographic changes. Data on BC outcomes were obtained from the 2019 Global Burden of Disease Survey. The age-period-cohort (APC) modeling technique was used to evaluate the nonlinear impacts of age, cohort, and period on BC outcomes and reported risk attributable mortality and disability adjusted life years (DALYs) rate changes between 1990 and 2019. In 2019, there were 0.90 million female BC cases and 0.35 million deaths in the BRICS-plus region, with China and India having the largest proportion of incident cases and deaths, followed by Pakistan. Lesotho experienced the highest annualized rates of change (AROC: 2.61%; 95%UI: 1.99-2.99) in the past three decades. Birth cohorts' impact on BC varies greatly between the BRICS-plus nations, with Pakistan suffering the largest risk increase in the most recent cohort. High body mass index (BMI), high fasting plasma glucose (FPG), and a diet high in red meat contributed to the highest death and DALYs rates in most BRICS-plus nations in 2019, and there was a strong negative link between SDI and death and DALYs rate. The study found that the burden of BC varies significantly between BRICS-plus regions. Thus, BRICS-plus nations should prioritise BC prevention, raise public awareness, and implement screening efficiency measures to reduce the burden of BC in the future, as well as strengthen public health policies and initiatives for important populations based on their characteristics and adaptability.
Sections du résumé
Background
UNASSIGNED
Breast cancer (BC) is a major health concern in the BRICS-plus, a group of developing nations consisting of Brazil, Russia, India, China, South Africa, and 30 other Asian countries, with nearly half of the world's population. This study aims to identify potential risk factors contributing to the burden of BC by assessing its epidemiological and socio-demographic changes.
Methods
UNASSIGNED
Data on BC outcomes were obtained from the 2019 Global Burden of Disease Survey. The age-period-cohort (APC) modeling technique was used to evaluate the nonlinear impacts of age, cohort, and period on BC outcomes and reported risk attributable mortality and disability adjusted life years (DALYs) rate changes between 1990 and 2019.
Results
UNASSIGNED
In 2019, there were 0.90 million female BC cases and 0.35 million deaths in the BRICS-plus region, with China and India having the largest proportion of incident cases and deaths, followed by Pakistan. Lesotho experienced the highest annualized rates of change (AROC: 2.61%; 95%UI: 1.99-2.99) in the past three decades. Birth cohorts' impact on BC varies greatly between the BRICS-plus nations, with Pakistan suffering the largest risk increase in the most recent cohort. High body mass index (BMI), high fasting plasma glucose (FPG), and a diet high in red meat contributed to the highest death and DALYs rates in most BRICS-plus nations in 2019, and there was a strong negative link between SDI and death and DALYs rate.
Conclusions
UNASSIGNED
The study found that the burden of BC varies significantly between BRICS-plus regions. Thus, BRICS-plus nations should prioritise BC prevention, raise public awareness, and implement screening efficiency measures to reduce the burden of BC in the future, as well as strengthen public health policies and initiatives for important populations based on their characteristics and adaptability.
Identifiants
pubmed: 37215157
doi: 10.1016/j.ssmph.2023.101418
pii: S2352-8273(23)00083-6
pmc: PMC10193025
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101418Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
All authors declare that no conflict of interest exists.
Références
Global Health. 2019 Jan 8;15(1):3
pubmed: 30621753
PLoS One. 2016 Oct 31;11(10):e0165409
pubmed: 27798652
Clinics (Sao Paulo). 2017 Apr;72(4):244-253
pubmed: 28492725
Biomed Res Int. 2022 Apr 18;2022:9605439
pubmed: 35480139
Lancet Oncol. 2021 Aug;22(8):1071-1080
pubmed: 34270924
Afr J Prim Health Care Fam Med. 2022 Dec 14;14(1):e1-e8
pubmed: 36546486
Lancet Glob Health. 2018 Aug;6(8):e885-e893
pubmed: 30012269
Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
Int J Environ Res Public Health. 2019 Oct 18;16(20):
pubmed: 31635366
PLoS Med. 2006 Feb;3(2):e18
pubmed: 16354108
PLoS One. 2017 Feb 13;12(2):e0171024
pubmed: 28192444
Popul Health Metr. 2012 Jan 06;10:1
pubmed: 22226226
Lancet. 2017 Sep 16;390(10100):1345-1422
pubmed: 28919119
Lancet. 2017 Sep 16;390(10100):1151-1210
pubmed: 28919116
Lancet Glob Health. 2015 Nov;3(11):e712-23
pubmed: 26475018
Breast Cancer Res Treat. 2014 Apr;144(3):467-78
pubmed: 24604092
Lancet. 2020 Oct 17;396(10258):1223-1249
pubmed: 33069327
JAMA. 2001 Nov 7;286(17):2143-51
pubmed: 11694156
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Lancet. 2017 Sep 16;390(10100):1211-1259
pubmed: 28919117
Bull World Health Organ. 1994;72(3):429-45
pubmed: 8062401
J Health Econ. 1997 Dec;16(6):703-30
pubmed: 10176780
Lancet. 2017 Sep 16;390(10100):1084-1150
pubmed: 28919115
Sci Rep. 2022 Nov 11;12(1):19301
pubmed: 36369336
Indian J Med Res. 2020 Oct;152(4):343-355
pubmed: 33380699
JAMA Oncol. 2019 Feb 1;5(2):155-163
pubmed: 30520976
Lancet Oncol. 2022 Jun;23(6):691
pubmed: 35654049
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Exp Biol Med (Maywood). 2021 Jun;246(12):1377-1387
pubmed: 33926257
Lancet. 2020 Oct 17;396(10258):1160-1203
pubmed: 33069325
J Hematol Oncol. 2019 Oct 22;12(1):107
pubmed: 31640759
Cancer Epidemiol. 2018 Aug;55:73-80
pubmed: 29843073
Stat Med. 1987 Jun;6(4):469-81
pubmed: 3629048
J Surg Oncol. 2011 Mar 1;103(3):217-22
pubmed: 21246565
Stat Med. 1987 Jun;6(4):449-67
pubmed: 3629047
J Epidemiol Glob Health. 2015 Sep;5(3):211-9
pubmed: 26231397
N Engl J Med. 2013 Aug 1;369(5):448-57
pubmed: 23902484
Breast Cancer Res Treat. 2016 Oct;159(3):395-406
pubmed: 27562585
Biometrics. 1983 Jun;39(2):311-24
pubmed: 6626659
Lancet. 2009 Jun 27;373(9682):2201-14
pubmed: 19560602
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Stat Med. 2007 Jul 10;26(15):3018-45
pubmed: 17177166
Adv Exp Med Biol. 2017;960:571-606
pubmed: 28585217
Lancet. 2018 Sep 29;392(10153):1138-1146
pubmed: 30173906
Stat Methods Med Res. 1992;1(3):317-37
pubmed: 1341663
BMJ. 2021 Feb 24;372:n256
pubmed: 33627312
BMC Cancer. 2022 Feb 23;22(1):203
pubmed: 35197002
Lancet. 2018 Nov 10;392(10159):1859-1922
pubmed: 30415748
Lancet. 2016 Oct 8;388(10053):1725-1774
pubmed: 27733285
Int J Cancer. 2020 Oct 15;147(8):2131-2141
pubmed: 32306390
Asian Pac J Cancer Prev. 2022 Jan 01;23(1):311-318
pubmed: 35092400
Asia Pac J Clin Oncol. 2017 Aug;13(4):289-295
pubmed: 28181405
Asian Pac J Cancer Prev. 2019 Oct 01;20(10):2909-2915
pubmed: 31653134
Circulation. 2016 Jan 26;133(4):422-33
pubmed: 26811272
Cad Saude Publica. 2015 Aug;31(8):1732-42
pubmed: 26375651
Breast Cancer Res Treat. 2018 Jun;169(3):595-606
pubmed: 29445940
Alcohol Alcohol. 2015 Jul;50(4):470-6
pubmed: 25882742
Nat Rev Cardiol. 2019 Apr;16(4):203-212
pubmed: 30467329
J Hematol Oncol. 2019 Dec 21;12(1):140
pubmed: 31864424